PUBLISHER: DelveInsight | PRODUCT CODE: 1468472
PUBLISHER: DelveInsight | PRODUCT CODE: 1468472
DelveInsight's " Malignant ascites - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Malignant ascites, historical and forecasted epidemiology as well as the Malignant ascites market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
The Malignant ascites market report provides current treatment practices, emerging drugs, Malignant ascites market share of the individual therapies, and current and forecasted Malignant ascites market size from 2020 to 2034, segmented by seven major markets. The report also covers current Malignant ascites treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Study Period: 2020-2034
Malignant ascites Overview
Malignant ascites (MA) is a pathological condition due to a variety of primary abdominal and extra-abdominal neoplasms. It is a primary cause of morbidity and presents many difficulties and treatment challenges. Malignant ascite is a sign of peritoneal carcinomatosis, the presence of malignant cells in the peritoneal cavity. Tumors causing carcinomatosis are more commonly secondary peritoneal surface malignancies, which include ovarian, colorectal, pancreatic, and uterine; extra-abdominal tumors originating from lymphoma, lung, and breast; and a small number of unknown primary tumors.
Malignant ascites Diagnosis
The causes of intra-abdominal fluid production are many, including cirrhosis, congestive heart failure, nephrosis, pancreatitis, peritonitis, primary malignancy, or hepatic metastases. It is not possible to distinguish benign ascites from malignant ascites by physical exam or radiographic techniques alone. Invasive testing is necessary to differentiate the two types. Abdominal paracentesis with ascitic fluid analyses can diagnose malignant causes of ascite production in most cases, but laparoscopic tissue sampling may be necessary. Recently, several molecular profiling studies aimed at examining the different contents of MA, such as soluble molecules (proteins, DNA, and RNA), extracellular vesicles (EVs), and cells, have provided new insights into the outcome of PDAC (pancreatic ductal adenocarcinoma) patients with MA.
Further details related to diagnosis will be provided in the report...
Malignant ascites Treatment
With only two approved therapies, i.e., OK-432 and KM-CART in Japan, most patients are limited to the best palliative care, which is often inadequate to address these unmet needs. Several treatment modalities can alleviate the symptoms associated with malignant ascites. Because the natural history of ascite formation is poorly understood, these measures and quality of life data are limited, and the efficacy of existing treatments is difficult to assess. Traditional modalities for managing malignant ascites include sodium-restricted diets, diuretic therapy, serial paracentesis, and peritoneovenous shunting.
Further details related to treatment will be provided in the report.....
The Malignant ascites epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by the total incident cases of Malignant ascites associated cancers, total patient pool of malignant ascites in the 7MM market covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.
The drug chapter segment of the Malignant ascites report encloses a detailed analysis of the early-stage (Phase I/II and Phase I), mid-stage (Phase II and Phase II/III), and late-stage (Phase III) pipeline drug. The current key players for emerging drugs and their respective drug candidates include Lindis Biotech (Catumaxomab), Wuhan YZY Biopharma (M701). The drug chapter also helps understand the Malignant ascites clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details, and the latest news and press releases.
Emerging Drugs
Catumaxomab: Lindis Biotech
Catumaxomab is a bispecific trifunctional antibody that binds directly to the tumor cell with one of its binding sites. It activates two essential components of the immune system with the other binding sites: T cells and macrophages (scavenger cells). The antibody recognizes and binds to all EpCAM-positive tumor cells, including critical cancer stem cells and all CD3-positive T cells. The EpCAM marker is present on almost all carcinomas and is, therefore, a promising approach for targeted cancer treatment. As per company pipeline, catumaxomab is in the preregistration stage of development for the treatment of Malignant ascites.
M 701: Wuhan YZY Biopharma
M701 is a new biological Class I drug that targets both EpCAM and CD3 being developed by YBODY Biotech through its independently patented asymmetric bispecific antibody YBODY(R) platform. The drug is mainly used for the treatment of malignant ascites (MA) and malignant pleural effusion (MPE) derived from EpCAM-positive cancer.M701 dual-antibody targets the EpCAM antigen on one end. At the same time, the CD3 antibody on the other end can bridge T cells and activate T cells to kill EpCAM-positive tumor cells. Currently, M701 is in the Phase II stage of development for the treatment of malignant ascites.
Drug Class Insight
Antibody-dependent cell cytotoxicity
Antibody-Dependent Cellular Cytotoxicity (ADCC) is a crucial mechanism of the immune system involving the targeting and destruction of pathogenic cells by effector cells, particularly natural killer (NK) cells. ADCC is a process where specific antibodies bind to pathogens, marking them for destruction by NK cells through the injection of cytotoxic factors, leading to cell lysis. Antibodies recognize and bind to target cells, which are then attacked and destroyed by effector cells like NK cells. This process plays a vital role in immune responses against pathogens and cancer cells.
With only two approved therapies, i.e., OK-432 and KM-CART in Japan, most patients are limited to the best palliative care, which is often inadequate to address these unmet needs.. Only few key players are active in the pipeline such as Lindis Biotech and Wuhan YZY Biopharma for the treatment of Malignant ascites.
OK-432 (Picibanil) is a freeze-dried biological product that is prepared from the Su strain of Streptococcus pyogenes (group A) by treatment with benzylpenicillin and heat. OK-432 has been reported to induce various cytokines, activate immunological cells, and thus augment anticancer immunity.
KM-CART is a novel cell-free and concentrated ascites reinfusion therapy. It is modified from a conventional CART approved by the Ministry of Health, Labor and Welfare in Japan. KM-CART is easier to use and can be applied for massive malignant ascites.
Detailed market assessment will be provided in the final report.
Key Findings
This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2024-2034. The landscape of Malignant ascites treatment has experienced a transformation with the uptake of novel drugs. These innovative therapies are redefining standards of care. Furthermore, the increased uptake of these transformative drugs is a testament to the unwavering dedication of physicians, oncologists and the entire healthcare community in their tireless pursuit of advancing care. This momentous shift in treatment paradigms is a testament to the power of research, collaboration, and human resilience.
Malignant ascites Pipeline Development Activities
The report provides insights into therapeutic candidates in Phase III, Phase II and Phase I. It also analyzes key players involved in developing targeted therapeutics. Companies like Lindis Biotech and Wuhan YZY Biopharma actively engage in late stage research and development efforts for Malignant ascites. The pipeline of Malignant ascites possesses few potential drugs. However, there is a positive outlook for the therapeutics market, with expectations of growth during the forecast period (2024-2034).
Pipeline Development Activities
The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Malignant ascites emerging therapy.
Market Access and Reimbursement
In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs, including Medicare, Medicaid, the Children's Health Insurance Program (CHIP), and the state and federal health insurance marketplaces, are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs), third-party organizations that provide services and educational programs to aid patients are also present.
A zero-dollar copay program is a healthcare initiative designed to eliminate out-of-pocket costs for patients when obtaining specific medical services or prescription medications. Under this program, individuals enrolled in health insurance plans or prescription drug benefit programs can access certain services or medications without having to make any direct financial contributions in the form of copayments. The program is often implemented to improve medication adherence and access to essential healthcare services, particularly for chronic conditions. Pharmaceutical manufacturers or healthcare providers may offer zero-dollar copay programs as a strategy to make necessary treatments more affordable and accessible for patients, ultimately enhancing overall health outcomes and patient satisfaction.
Detailed market access and reimbursement assessment will be provided in the final report.
FAQs